Collegium’s Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham
1
0
Needham analyst Serge Belanger upgraded Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to Buy from Hold, with a price forecast of $46.
Recently, Collegium provided 2025 guidance, expecting a top-line of $735 million – $750 million, including Jornay PM sales over $135 million and adjusted EBITDA of $435 million – $450 million.
The analyst highlights that the guidance was higher than their estimates and aligned with Street consensus.
Per the analyst, the company’s valuation doesn’t fully reflect its growth, profitability, and cash flow, boosted by Jornay PM’s expected contribution.
Belanger also highlighted that the company’s valuation presents an attractive entry point, and that the continued …
Full story available on Benzinga.com
Visited 1 times, 1 visit(s) today